Zoology

2 N.C. Veterinary Hospitals Join Vets Pets; Brings to 30 the Number of Practices Belonging to the Multifaceted Support Network

Retrieved on: 
Wednesday, June 22, 2022

The two newest Vets Pets member hospitals are co-owned by Vets Pets and veterinarians who joined at the partner level.

Key Points: 
  • The two newest Vets Pets member hospitals are co-owned by Vets Pets and veterinarians who joined at the partner level.
  • Jacob Mauck, DVM, will open Crown Town Animal Hospital and Keri Reeves, DVM, will start Kindred Heart Animal Hospital.
  • It is a ton of fun and extremely rewarding to create something new and personal for both Vets Pets and our partners."
  • Before enrolling in veterinary school, Dr. Reeves graduated summa cum laude with a degree in biology from Stonehill College, Massachusetts.

Judith C. Milstead, MD, FACS, is recognized by Continental Who's Who

Retrieved on: 
Monday, June 20, 2022

Dr. Milstead has been working as a surgeon for 40 years, performing soft tissue surgeries at Lake Ear Nose Throat & Facial Plastic Surgery.

Key Points: 
  • Dr. Milstead has been working as a surgeon for 40 years, performing soft tissue surgeries at Lake Ear Nose Throat & Facial Plastic Surgery.
  • She always listens to her patient's questions and concerns and tells them the process for their treatment to alleviate any worries.
  • At Lake Ear Nose Throat & Facial Plastic Surgery, Dr. Milstead works with a talented team of physicians and nurses to provide exceptional healthcare for every patient.
  • Lake Ear Nose Throat & Facial Plastic Surgery has three locations throughout Florida: Leesburg Medical Plaza, Tavares, and The Villages.

BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer

Retrieved on: 
Thursday, June 16, 2022

TEL AVIV, Israel, June 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has appointed biopharmaceutical veteran executive Holly W. May as its Chief Commercial Officer. In this newly created role, based in the U.S., Ms. May will be responsible for the commercial planning, positioning and launch oversight for Motixafortide in the stem cell mobilization indication across the U.S. market, assuming FDA approval.

Key Points: 
  • BioLineRx remains on track to submit its New Drug Application to the FDA in mid-2022, consistent with prior guidance.
  • Prior to joining BioLineRx, Ms. May served as Chief Commercial Officer at AVROBIO since September 2019, where she was responsible for building the company's global commercial organization and over-arching commercial capabilities, inclusive of driving the development and execution of commercial strategy.
  • Prior to that, she served as Vice President and Head of Commercial at SOBI, Inc., where she led all aspects of commercial strategy, operations and performance.
  • BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

AAUW To Offer Free STEM Program for High School Girls

Retrieved on: 
Tuesday, May 31, 2022

With a particular focus on girls of color, AAUW STEMEd for Girls virtual summer sessions seek to pave the way for students success in college and beyond.

Key Points: 
  • With a particular focus on girls of color, AAUW STEMEd for Girls virtual summer sessions seek to pave the way for students success in college and beyond.
  • Only 11% of teen girls say they plan to pursue a STEM career, compared to 35% of boyswe need to change that, said AAUW CEO Gloria L. Blackwell.
  • This program will give more girls access to resources and connections and will show them how accessible and exciting STEM fields can be.
  • Taking place from June 1-July 20, AAUW STEMEd for Girls will feature sessions for girls, each focusing on a main STEM subject.

USOSM Salutes Dr. Wendell “Wedge” Edgin for 42 years of clinical practice, as he announces his intention to retire

Retrieved on: 
Thursday, April 28, 2022

IRVING, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- After 42 years of clinical practice, Wendell Wedge Edgin, DDS, FICD, FACD, has announced his intention to retire from Alamo Maxillofacial Surgical Associates, effective May 1, 2022.

Key Points: 
  • IRVING, Texas, April 28, 2022 (GLOBE NEWSWIRE) -- After 42 years of clinical practice, Wendell Wedge Edgin, DDS, FICD, FACD, has announced his intention to retire from Alamo Maxillofacial Surgical Associates, effective May 1, 2022.
  • Oral Surgery Management (USOSM), with three locations, treating patients in San Antonio and Boerne, Texas.
  • This will be a big change for me and my family, but getting to spend more time together is something were looking forward to, said Dr. Edgin.
  • He is well-known throughout the Texas Hill Country and the oral and maxillofacial surgery (OMS) industry for his dedication, experience and clinical expertise.

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

Retrieved on: 
Tuesday, April 19, 2022

BOSTON and CAMERINO, Italy, April 19, 2022 /PRNewswire-PRWeb/ -- The University of Camerino (UniCam) has extended its strategic business partnership with CureLab Oncology Inc., a clinical-stage biotech company, to develop anti-cancer immunotherapy for humans, and has signed a similar agreement with CureLab Veterinary Inc., to reapply this medicine for treatment of companion animals.

Key Points: 
  • BOSTON and CAMERINO, Italy, April 19, 2022 /PRNewswire-PRWeb/ -- The University of Camerino (UniCam) has extended its strategic business partnership with CureLab Oncology Inc. , a clinical-stage biotech company, to develop anti-cancer immunotherapy for humans, and has signed a similar agreement with CureLab Veterinary Inc. , to reapply this medicine for treatment of companion animals.
  • Given this success, CureLab Oncology and UniCam have agreed to extend their partnership.
  • "This new partnership with CureLab Veterinary, based on both scientific and clinical strength, brings attractive development opportunities for the entire school."
  • CureLab Veterinary has an exclusive license for application of CureLab Oncology IP to dogs, cats and horses.

Richard Green Joins Dorsey’s Salt Lake City Office

Retrieved on: 
Tuesday, April 12, 2022

International law firm Dorsey & Whitney LLP continues its expansion of its Intellectual Property Practice in Salt Lake City with the addition of Richard Green as Of Counsel.

Key Points: 
  • International law firm Dorsey & Whitney LLP continues its expansion of its Intellectual Property Practice in Salt Lake City with the addition of Richard Green as Of Counsel.
  • View the full release here: https://www.businesswire.com/news/home/20220412005904/en/
    Richard Green has joined Dorsey's Salt Lake City office as Of Counsel in its Intellectual Property Practice Group.
  • Before joining Dorsey, Richard was of counsel with Stoel Rives in Salt Lake City.
  • He is an excellent addition to our already strong patent and trademark group in Salt Lake City.

Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

Retrieved on: 
Thursday, March 31, 2022

His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy.

Key Points: 
  • His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy.
  • Sigyn Therapy is an extracorporeal blood purification technology being advanced to treat life-threatening inflammatory disorders.
  • Dr. Verma most recently headed R&D efforts at Yumanity Therapeutics, developing drugs against novel targets for treating neurodegenerative diseases.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

New COO helping realize Seattle Humane’s five-year strategic vision

Retrieved on: 
Tuesday, March 29, 2022

Bellevue, Washington, March 29, 2022 (GLOBE NEWSWIRE) -- Seattle Humanes new Chief Operations Officer Libby Jones is helping the 125-year-old nonprofit realize its five-year strategic vision developed last year, which relies heavily on first investing in the people that power the organizations mission and purpose.

Key Points: 
  • Bellevue, Washington, March 29, 2022 (GLOBE NEWSWIRE) -- Seattle Humanes new Chief Operations Officer Libby Jones is helping the 125-year-old nonprofit realize its five-year strategic vision developed last year, which relies heavily on first investing in the people that power the organizations mission and purpose.
  • Seattle Humanes five-year strategic vision, which was spearheaded by CEO Christopher Ross shortly after joining the organization in January 2021, reflects the evolving landscape in animal welfare and recognizes a community-focused approach is necessary in supporting pets and their owners.
  • We are excited to see how she applies her skills and experience to set Seattle Humane up for another 125 years of success.
  • Seattle Humanes strategic vision rests in five key pillars, one of which is to invest in their people by promoting fulfilling careers and livable wages in animal welfare.

Lisa K. Longhofer, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, March 31, 2022

Dr. Lisa K. Longhofer has been working as an Orthopedic Hand Surgeon and Upper Extremity Surgeon for the past 12 years, helping patients in the Amarillo, TX, area.

Key Points: 
  • Dr. Lisa K. Longhofer has been working as an Orthopedic Hand Surgeon and Upper Extremity Surgeon for the past 12 years, helping patients in the Amarillo, TX, area.
  • Dr. Longhofer grew up on a cattle ranch near Canadian, TX, where she graduated high school as the Valedictorian.
  • She attended Texas Tech University, earning a Bachelor of Science degree in Zoology, graduating Summa Cum Laude in 2003.
  • To continue her training, Dr. Longhofer completed an Orthopedic Surgery residency at the University of Kansas from 2008 - 2013.